Trial Profile
ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Maraviroc (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Acronyms ENLIGHTEN
- 09 Jan 2023 Results assessing PrEP Adherence Monitoring Using Dried Blood Spots published in the Clinical Pharmacology and Therapeutics
- 10 Mar 2021 Results assessing daily adherence to maraviroc-based PrEP regimens from samples obtained from trial HPTN069/ACTG5305 and benchmarking was performed in samples obtained from ENLIGHTEN trial presented at the 28th Conference on Retroviruses and Opportunistic Infections
- 11 Mar 2020 Results (n=12) assessing long-term adherence monitoring of emtricitabine in hair by mass spectrometry imaging, presented at the 27th Conference on Retroviruses and Opportunistic Infections